ATE326964T1 - Aminosäurederivate zur behandlung der alzheimer- krankheit - Google Patents

Aminosäurederivate zur behandlung der alzheimer- krankheit

Info

Publication number
ATE326964T1
ATE326964T1 AT02804013T AT02804013T ATE326964T1 AT E326964 T1 ATE326964 T1 AT E326964T1 AT 02804013 T AT02804013 T AT 02804013T AT 02804013 T AT02804013 T AT 02804013T AT E326964 T1 ATE326964 T1 AT E326964T1
Authority
AT
Austria
Prior art keywords
sub
disease
alzheimer
treatment
amino acid
Prior art date
Application number
AT02804013T
Other languages
English (en)
Inventor
Varghese John
Original Assignee
Elan Pharm Inc
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Pharmacia & Upjohn Co Llc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE326964T1 publication Critical patent/ATE326964T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02804013T 2001-11-21 2002-11-21 Aminosäurederivate zur behandlung der alzheimer- krankheit ATE326964T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33469201P 2001-11-21 2001-11-21

Publications (1)

Publication Number Publication Date
ATE326964T1 true ATE326964T1 (de) 2006-06-15

Family

ID=23308367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804013T ATE326964T1 (de) 2001-11-21 2002-11-21 Aminosäurederivate zur behandlung der alzheimer- krankheit

Country Status (10)

Country Link
US (1) US20060079550A1 (de)
EP (1) EP1458378B1 (de)
JP (1) JP2005514370A (de)
AT (1) ATE326964T1 (de)
AU (1) AU2002356991A1 (de)
BR (1) BR0214359A (de)
CA (1) CA2477585A1 (de)
DE (1) DE60211746D1 (de)
MX (1) MXPA04004903A (de)
WO (1) WO2003045378A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325205T3 (es) * 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
CA2535337A1 (en) * 2003-08-14 2005-03-03 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
AU2004277981B2 (en) * 2003-10-03 2009-10-01 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease
CA2544350A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
WO2005051914A1 (en) * 2003-11-24 2005-06-09 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
NZ562314A (en) 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP2285774B1 (de) 2008-06-05 2015-02-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Neue modulatoren der proteinkinasesignalisierung
CN103242200A (zh) * 2013-04-10 2013-08-14 吉尔生化（上海）有限公司 一种Nα-芴甲氧羰基-Nε-乙酰基-赖氨酸的制备方法
EP3021944B1 (de) 2013-07-14 2018-12-19 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Igf-1r signalweginhibitoren zur behandlung von neurodegenerativen erkrankungen
JP2018504418A (ja) 2015-02-05 2018-02-15 ティルノーヴォ リミテッド 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ
CN109265371A (zh) * 2018-10-12 2019-01-25 吉尔生化（上海）有限公司 一种Nα-[(9H-芴-9-基甲氧基)羰基]-Nε-乙酰基-L-赖氨酸的制备方法
CN109824547A (zh) * 2019-03-20 2019-05-31 康化（上海）新药研发有限公司 一种双不同保护氨基酸的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5986102A (en) * 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
KR20070013361A (ko) * 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors

Also Published As

Publication number Publication date
JP2005514370A (ja) 2005-05-19
US20060079550A1 (en) 2006-04-13
WO2003045378A1 (en) 2003-06-05
AU2002356991A1 (en) 2003-06-10
EP1458378B1 (de) 2006-05-24
CA2477585A1 (en) 2003-06-05
EP1458378A1 (de) 2004-09-22
MXPA04004903A (es) 2005-06-06
BR0214359A (pt) 2004-10-13
DE60211746D1 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA04003245A (es) Hidroxipropilaminas.
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
WO2003103653A8 (en) Methods of treating alzheimer's disease using aryl alkanoic acid amides
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
WO2003057721A3 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
UA84407C2 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
ATE323084T1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
BR0213743A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
WO2004029019A3 (en) Compounds for the treatment of alzheimer’s disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties